MRNA

Moderna, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1682852Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$1.94B

Net Income FY2025

$(2.82B)

EPS (Basic, as reported)

$-7.26

Net Margin FY2025

-145.2%

ROE FY2025

-32.6%

Total Equity

$8.65B

Shares Out

399M

Business description

Moderna, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2016–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 108 → 1,944 +37.9% CAGR

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue1082061356080318,47119,2636,8483,2361,944

Cost of revenue——00(8)(2,617)(5,416)(4,693)(1,464)(868)

Research & development(275)(410)(454)(496)(1,370)(1,991)(3,295)(4,845)(4,543)(3,132)

General & administrative(57)(65)(94)(110)(188)(567)(1,132)(1,549)(1,174)(1,018)

Total operating expenses(332)(475)(548)(606)(1,567)(5,175)(9,843)(11,087)(7,181)(5,018)

Operating income(224)(269)(413)(546)(763)13,2969,420(4,239)(3,945)(3,074)

Interest & investment income111527392518200421425314

Other income (expense), net(3)(2)2(8)(6)(29)(45)(124)(87)(8)

Pre-tax income(215)(256)(384)(515)(744)13,2859,575(3,942)(3,607)(2,768)

Income tax expense(1)00(1)(3)(1,083)(1,213)(772)(46)(54)

Net income(216)(256)(385)(514)(747)12,2028,362(4,714)(3,561)(2,822)

EPS — basic———($1.55)($1.96)$30.31$21.26($12.33)($9.28)($7.26)

EPS — diluted———($1.55)($1.96)$28.29$20.12($12.33)($9.28)($7.26)

Shares outstanding — basic (M)———331381403394382384389

Shares outstanding — diluted (M)———331381431416382384389

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.